Nuclein

BTNX INC.



DASH® Flu A/B Test

FDA-Cleared & CLIA Waived

The DASH® Flu A/B Test provides qualitative PCR test results in 15 minutes at the point of care allowing you to test and treat with increased confidence in a single patient visit.

Why Choose the DASH® Flu A/B Test?

- Reduce over- and under-treatment with 15-minute CLIA-waived point-of-care PCR testing
- Eliminate empiric treatment by equipping your team with lab-quality results
- Improve antimicrobial stewardship and HEDIS compliance
- Anterior nasal swab sample collection rather than more invasive nasopharyngeal swabs
- Test up to 30 specimens per 8-hour shift*
- Self- and clinician-collected specimens

* The DASH® Flu A/B Test requires up to 1 minute of hands-on time and has a 15-minute test time, which allows for up to 30 tests to be processed in a standard 8-hour workday.



Affordably priced to support lab-quality PCR testing at the point of care.

Flu A/B PCR Testing | **CPT Code: 87502**

National Medicare reimbursement*: $95.80 *CMS Fee Schedule. Q1'25. Maximum reimbursement rate.

Nuclein

DASH® Flu A/B Test

FDA Cleared & CLIA Waived | 15-Minute Runtime | PCR at the POC

Results From a Prospective Clinical Study Against an FDA-Cleared PCR Test

POSITIVE AGREEMENT *(Sensitivity)*		NEGATIVE AGREEMENT *(Specificity)*	
Flu A	94.3%	Flu A	98.1%
Flu B	97.3%	Flu B	99.2%

Source: DASH® Flu A/B Test package insert.

Intended Use

The DASH® Flu A/B Test is a rapid reverse transcription polymerase chain reaction (RT-PCR) assay performed on the DASH® Rapid PCR Instrument and is intended for the simultaneous in vitro qualitative detection and differentiation of influenza A and influenza B virus ribonucleic acid (RNA) in anterior nasal swab specimens from patients with signs and symptoms of respiratory tract infection. The test is intended to aid in the differential diagnosis of influenza A, and influenza B in humans in conjunction with other clinical, epidemiologic and laboratory findings and is not intended to detect influenza C.

Positive results of a specific target are indicative of the presence of that viral RNA and may not be the definite cause of disease. Positive results do not rule out co-infection with other pathogens. Negative results do not preclude influenza infection and should not be used as the sole basis for diagnosis, treatment or other patient management decisions.

Performance characteristics for influenza A were established during the 2023-2024 influenza season when influenza A/H3 and A/H1N1 pandemic were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary.

If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL3+ facility is available to receive and culture specimens.



DASH® Rapid PCR System

Test and Treat in a Single Patient Visit

1. PATIENT ARRIVES AND SAMPLE IS COLLECTED
2. RUN DASH® FLU A/B TEST
3. RESULTS IN JUST 15 MINUTES
4. CLINICIAN PRESENTS RESULTS AND DISCUSSES TREATMENT PLAN

sales@btnx.com | 1-888-339-9964 | www.btnx.com

©Nuclein, LLC 2025